Search for Clinical Trial Results
Pulmonary Alveolar Proteinosis - 24 Studies Found
Status | Study |
Active, not recruiting |
Study Name: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan Condition: Pulmonary Alveolar Proteinosis, Autoimmune Date: 2016-07-13 Interventions:
|
Not yet recruiting |
Study Name: Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis Condition: Autoimmune Pulmonary Alveolar Proteinosis Date: 2016-11-28 Interventions: Drug: Sargramostim Other Names:
|
Recruiting |
Study Name: Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Condition: Autoimmune Pulmonary Alveolar Proteinosis Date: 2016-02-28 Interventions:
|
Recruiting |
Study Name: Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis Condition:
Date: 2007-10-31 Interventions: Drug: rituximab IV, 1000 mg, two weeks, 2 times Othe |
Recruiting |
Study Name: Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. Condition: Pulmonary Alveolar Proteinosis Date: 2013-11-07 Interventions:
|
Recruiting |
Study Name: Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT Condition: Pulmonary Alveolar Proteinosis Date: 2014-02-12 |
Completed |
Study Name: SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study Condition: Pulmonary Alveolar Proteinosis, Autoimmune Date: 2016-07-13 Interventions: Drug: Sargramostim |
Recruiting |
Study Name: Rituximab for Anti-cytokine Autoantibody-Associated Diseases Condition:
Date: 2013-04-25 Interventions: Drug: Rituximab/Rituxan Rituximab is a genetically engineered chimeric murine/human monoclonal antibody |
Completed |
Study Name: Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Condition:
|
Recruiting |
Study Name: European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank Condition:
Date: 2016-07-29 |